Mepolizumab subcutaneous (SC) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.45 [0.36, 0.55]2 studies · 936 participantsHigh